Announces Prostate Cancer cells Data on RES-529, a Double TORC1/TORC2 Prevention
Jun 24, 2015
(GlobeNewswire) – RestorGenex Firm (OTC: RESX), a specialized biopharmaceutical firm concentrated on developing items for oncology, ophthalmology and also dermatology, revealed that Claudio Festuccia, Division of Professional Sciences as well as Applied Medical, Università degli Studi dell’Aquila, offered data on June 22, 2015 at the XXVth National Congress of the Italian … (proceed reading)
No comments:
Post a Comment